

ANSWERING REVIEWERS

October 1, 2020

Dear Editor,



Please find enclosed the edited manuscript in Word format (59400_Auto_Edited).

Title: Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports

Author: Masaki Okajima, Yoshinori Takahashi, Takaaki Kaji, Naohiko Ogawa, Hideyuki Mouri

Name of Journal: *World Journal of Clinical Cases*

ESPS Manuscript NO: 59400

I would like to respond to comment of reviewer:

Response for reviewer #1

The original comments of reviewer #1 are as follows.

Specific Comments to Authors: After Nafamostat Mesylate treatment, the authors observed that patients with COVID-19 pneumonia caused hyperkalemia. It is suggested that serum potassium should be closely monitored for such patients. As there are only four cases, it is recommended that information be continued.

Response: We really appreciated for your comments and suggestion. We will continue collecting data according to NM-induced hyperkalemia in COVID-19 patients with severe respiratory failure.

Thank you again for publishing our manuscript in the *World Journal of Clinical Cases*.

Sincerely yours,

Masaki Okajima, MD, PhD
Intensive Care Unit
Kanazawa University Hospital
13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan
E-mail: mmokaji@gmail.com